[
    {
        "file_name": "MACROGENICSINC_08_02_2013-EX-10-COLLABORATIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "1.18 \"Commercially Reasonable Efforts\" means with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective of such Party under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of MGAH22 and Products, such efforts shall be similar to those efforts and resources commonly used by a Party for a similar biological or pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved.",
                "changed_text": "1.18 \"Commercially Reasonable Efforts\" means with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, minimal efforts to accomplish such objective, regardless of whether such Party would normally expend such minimal efforts to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of MGAH22 and Products, such efforts shall be dissimilar to those efforts and resources commonly used by a Party for a similar biological or pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved.",
                "explanation": "The original text defines 'Commercially Reasonable Efforts' as a standard of reasonable and good faith effort, similar to what a party would normally use. The modified text contradicts this by defining it as 'minimal efforts', creating uncertainty about the actual effort required.",
                "location": "Section 1.18"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "10.3 License to MacroGenics. Green Cross hereby grants to MacroGenics a royalty-free, worldwide license during the Term, with the right to grant sublicenses, under the Green Cross Licensed Patents and Green Cross Know-how that is incorporated into any Product, and all other intellectual property Controlled by Green Cross that is specifically related to MGAH22 to the extent needed by MacroGenics to research, identify, develop, make, have made, use, sell, offer for sale and import Products, including, without limitation, as contemplated by Section 10.1(c) above, in all cases without any obligation to obtain Green Cross' prior consent. The license granted pursuant to this Section 10.3 shall be nonÂ­exclusive in the Territory and exclusive in the rest of the world outside the Territory. After the Term, the Parties shall discuss in good faith whether future licenses are necessary for MacroGenics to continue to use Green Cross Licensed Patents or Green Cross Licensed Know-how, and determine reasonable terms and conditions for such license at MacroGenics' request.",
                "changed_text": "10.3 License to MacroGenics. Green Cross hereby grants to MacroGenics a royalty-bearing license, limited to South Korea during the next quarter, without the right to grant sublicenses, under the Green Cross Licensed Patents and Green Cross Know-how that is incorporated into a single Product, and all other intellectual property Controlled by Green Cross that is specifically related to MGAH22 to the extent needed by MacroGenics for internal research. The license granted pursuant to this Section 10.3 shall be exclusive in the Territory and non-exclusive in the rest of the world outside the Territory. After the Term, the license to MacroGenics shall automatically renew without further action.",
                "explanation": "The original text grants a royalty-free, worldwide license to MacroGenics. The modified version directly contradicts this by making the license royalty-bearing, limited to the Territory and for a single quarter, and removes the right to sublicense, and adds automatic license renewal, creating significant uncertainty regarding the scope and duration of the license.",
                "location": "Section 10.3"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "11. EXCLUSIVITY. During the Term, Green Cross shall not (either by itself, or with or through a Related Party or Third Party) Develop or Commercialize any (i) Product outside of the scope of this Agreement or (ii) Competing Product.",
                "changed_text": "11. EXCLUSIVITY. During the Term, Green Cross is encouraged (either by itself, or with or through a Related Party or Third Party) to Develop or Commercialize any (i) Product outside of the scope of this Agreement and (ii) Competing Product.",
                "explanation": "Section 11 originally states that Green Cross shall not Develop or Commercialize any Product or Competing Product outside the scope of the agreement, however the changed version dictates that they are encouraged to do so. This contradiction will cause uncertainty.",
                "location": "Section 11"
            }
        ]
    }
]